MedPath

Personalized GI Motility Responses to Diet

Not Applicable
Recruiting
Conditions
Cardiovascular Diseases
Dysbiosis
Gastrointestinal Dysfunction
Nutritional and Metabolic Diseases
Interventions
Other: Refined grain rye bread
Other: Whole grain rye bread
Registration Number
NCT06386471
Lead Sponsor
University of Illinois at Urbana-Champaign
Brief Summary

The goal of this randomized, crossover, clinical trial is to link: 1) gastrointestinal motility patterns induced by acute consumption of whole and refined grains, 2) enteric microbial production of bioactive metabolites, and 3) circulating postprandial appearance of metabolites important to cardiometabolic health including glucose, triglycerides, and cholesterol.

Participants will be asked to consume a Smartpill monitoring device that records metrics of gastrointestinal motility in response to whole or refined grains, monitor cardiometabolic metabolties over an 8 hour postprandial window, and provide a fecal sample for microbiome-related analyses.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Healthy men and women
Exclusion Criteria

Physician-Diagnosed:

  • Diabetes Mellitus
  • Nutrient-malabsorption disorders
  • Intestinal Bowel Syndrome (IBS)
  • Intestinal Bowel Disease (IBD)
  • Bleeding-related disorders
  • Grain allergy
  • Psychological Disorders
  • Stenosis
  • Dysphasia

History of:

  • Bariatric Surgery
  • Gallbladder removal
  • Eating disorders
  • Antibiotic administration (within the past three months)
  • Hormone therapy

Currently:

  • Using statins
  • Pregnant, lactating, or postmenopausal
  • Taking oral hypoglycemic agents or insulin
  • Ingesting prescription fiber
  • Using cholesterol and bile acid absorption inhibitors
  • Ingesting nutrition supplements, not including a daily multivitamin (i.e. herbs, tinctures, and extracts) •Using recreational drugs or alcohol (within the past week)
  • Taking anti-histamines
  • Taking proton pump inhibitors
  • Taking antacids

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Refined grain rye breadRefined grain rye bread4.3 ounces of white rye bread, consumed after an overnight fast (12+ hours)
Whole grain rye breadWhole grain rye bread4.3 ounces of whole grain rye bread, consumed after an overnight fast (12+ hours)
Primary Outcome Measures
NameTimeMethod
Luminal pH (pH units)From consumption of bread and Smartpill to deification (single meal consumption, GI motility times vary based on participant, but could be estimated from around 16 hours to 5 days)

pH of gastrointestinal contents as captured by the Medtronic Smartpill capsule

Temperature (degrees celcius)From consumption of bread and Smartpill to deification (single meal consumption, GI motility times vary based on participant, but could be estimated from around 16 hours to 5 days)

Temperature in the intestinal lumen as captured by the Medtronic Smartpill capsule

Gastrointestinal Pressure (mmHg)From consumption of bread and Smartpill to deification (single meal consumption, GI motility times vary based on participant, but could be estimated from around 16 hours to 5 days)

Pressure of gastrointestinal contractions as captured by the Medtronic Smartpill capsule temperature, transit time)

Gastrointestinal Transit Time (hours:minutes)From consumption of bread and Smartpill to deification (single meal consumption, GI motility times vary based on participant, but could be estimated from around 16 hours to 5 days)

Duration of gastrointestinal transit as captured by the Medtronic Smartpill capsule

Total CholesterolBaseline to 8 hours post bread and Smartpill consumption (baseline, 0.5 hours, 1 hour, 1.5 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, and 8 hours)

Concentration of total cholesterol in whole blood from finger prick as measured by the Konsung Portable Dry Biochemical Analyzer

LDL cholesterolBaseline to 8 hours post bread and Smartpill consumption (baseline, 0.5 hours, 1 hour, 1.5 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, and 8 hours)

Concentration of LDL choelsterol in whole blood from finger prick as measured by the Konsung Portable Dry Biochemical Analyzer

Blood GlucoseBaseline to 8 hours post bread and Smartpill consumption (baseline, 0.5 hours, 1 hour, 1.5 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, and 8 hours)

Concentration of glucose in whole blood from finger prick as measured by the Konsung Portable Dry Biochemical Analyzer

TriglyceridesBaseline to 8 hours post bread and Smartpill consumption (baseline, 0.5 hours, 1 hour, 1.5 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, and 8 hours)

Concentration of triglycerides in whole blood from finger prick as measured by the Konsung Portable Dry Biochemical Analyzer

HDL cholesterolBaseline to 8 hours post bread and Smartpill consumption (baseline, 0.5 hours, 1 hour, 1.5 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, and 8 hours)

Concentration of HDL cholesterol in whole blood from finger prick as measured by the Konsung Portable Dry Biochemical Analyzer

Lipopolysaccharide Binding ProteinBaseline to 8 hours post bread and Smartpill consumption (baseline, 0.5 hours, 1 hour, 1.5 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, and 8 hours)

Concentration of LBP in whole blood from finger prick as measured by ELISA

Secondary Outcome Measures
NameTimeMethod
MicrobiomeFecal sample following ingestion of the Smartpill and test meal (approximately 24 hours into the study arm)

Shotgun metagenomic sequencing of fecal samples, including metrics of diversity (ex: shannon index), taxonomic abundances (relative abundance, %), functional gene abundances (relative abundance, %), etc

MetabolomicsFecal sample following ingestion of the Smartpill and test meal (approximately 24 hours into the study arm)

Untargeted metabolomics of fecal samples via LC-MS, including metrics of pathway analysis (pathway score), single metabolite relative concentration (relative intensity), etc

Trial Locations

Locations (1)

University of Illinois at Urbana-Champaign

🇺🇸

Urbana, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath